Table 2.
Steady-state ritonavir pharmacokinetic parameters
| Study day | AUC0-12 (mg·h/liter) [median (IQR)] | Geometric mean ratio (90% CI) | Cmax (mg/liter) [median (IQR)] | Geometric mean ratio (90% CI) | t1/2 (h) (mean ± SD) | C0 (mg/liter) [median (IQR)] | C12 (mg/liter) [median (IQR)] |
|---|---|---|---|---|---|---|---|
| 1 | 5.8 (3.9–8.5) | Referent | 1.2 (0.8–1.9) | Referent | 3.5 (3.2–4.6) | 0.33 (0.18–0.55) | 0.13 (0.10–0.18) |
| 8 | 2.2 (1.5–3.7) P < 0.00a,b | 0.39 (0.34–0.42) | 0.5 (0.4–0.9) P < 0.001a,b | 0.44 (0.38–0.51) | 2.6 (2.2–2.8) P < 0.001a,b | 0.09 (0.03–0.16) | 0.03 (0.01–0.05) |
| 15 | 4.8 (2.5–9.6) P = 0.63a,b | 0.85 (0.71–1.01) | 1.1 (0.7–2.2) P = 0.60a,b | 0.90 (0.73–1.11) | 2.7 (1.9–3.2) P < 0.001a,b | 0.31 (0.10–0.70) | 0.06 (0.03–0.15) |
| 22 | 7.6 (4.2–13.2) P = 0.004a,b | 1.42 (1.20–1.67) | 2.0 (1.4–3.1) P = 0.002a,b | 1.54 (1.27–1.88) | 2.8 (2.4–3.3) P < 0.003a,b | 0.63 (0.37–1.11) | 0.11 (0.05–0.25) |
a
Compared with study day 1.
b
Wilcoxon signed-rank test.